Literature DB >> 14654047

Advanced glycation end product ligands for the receptor for advanced glycation end products: biochemical characterization and formation kinetics.

Jessica V Valencia1, Stephen C Weldon, Douglas Quinn, Geesje H Kiers, Jeroen DeGroot, Johan M TeKoppele, Thomas E Hughes.   

Abstract

Advanced glycation end products (AGEs) accumulate with age and at an accelerated rate in diabetes. AGEs bind cell-surface receptors including the receptor for advanced glycation end products (RAGE). The dependence of RAGE binding on specific biochemical characteristics of AGEs is currently unknown. Using standardized procedures and a variety of AGE measures, the present study aimed to characterize the AGEs that bind to RAGE and their formation kinetics in vitro. To produce AGEs with varying RAGE binding affinity, bovine serum albumin (BSA) AGEs were prepared with 0.5M glucose, fructose, or ribose at times of incubation from 0 to 12 weeks or for up to 3 days with glycolaldehyde or glyoxylic acid. The AGE-BSAs were characterized for RAGE binding affinity, fluorescence, absorbance, carbonyl content, reactive free amine content, molecular weight, pentosidine content, and N-epsilon-carboxymethyl lysine content. Ribose-AGEs bound RAGE with high affinity within 1 week of incubation in contrast to glucose- and fructose-AGE, which required 12 and 6 weeks, respectively, to generate equivalent RAGE ligands (IC50=0.66, 0.93, and 1.7 microM, respectively). Over time, all of the measured AGE characteristics increased. However, only free amine content robustly correlated with RAGE binding affinity. In addition, detailed protocols for the generation of AGEs that reproducibly bind RAGE with high affinity were developed, which will allow for further study of the RAGE-AGE interaction.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14654047     DOI: 10.1016/j.ab.2003.09.013

Source DB:  PubMed          Journal:  Anal Biochem        ISSN: 0003-2697            Impact factor:   3.365


  43 in total

1.  A receptor-based bioadsorbent to target advanced glycation end products in chronic kidney disease.

Authors:  Yangrong Zhang; Karen A Lapidos; Anca Gal-Moscovici; Stuart M Sprague; Guillermo A Ameer
Journal:  Artif Organs       Date:  2013-11-11       Impact factor: 3.094

2.  Advanced glycation end products in myocardial reperfusion injury.

Authors:  Peter Celec; Július Hodosy; Peter Jáni; Pavol Janega; Matúš Kúdela; Marta Kalousová; Johana Holzerová; Vojtech Parrák; Lukáč Halčák; Tomáš Zima; Martin Braun; Ivan Pecháň; Ján Murín; Katarína Šebeková
Journal:  Heart Vessels       Date:  2011-05-12       Impact factor: 2.037

Review 3.  Effects of age-related shifts in cellular function and local microenvironment upon the innate immune response to implants.

Authors:  Bryan N Brown; Martin J Haschak; Samuel T Lopresti; Elizabeth C Stahl
Journal:  Semin Immunol       Date:  2017-05-20       Impact factor: 11.130

4.  Positron emission tomography probe demonstrates a striking concentration of ribose salvage in the liver.

Authors:  Peter M Clark; Graciela Flores; Nikolai M Evdokimov; Melissa N McCracken; Timothy Chai; Evan Nair-Gill; Fiona O'Mahony; Simon W Beaven; Kym F Faull; Michael E Phelps; Michael E Jung; Owen N Witte
Journal:  Proc Natl Acad Sci U S A       Date:  2014-06-30       Impact factor: 11.205

5.  Below the radar: advanced glycation end products that detour "around the side". Is HbA1c not an accurate enough predictor of long term progression and glycaemic control in diabetes?

Authors:  Josephine M Forbes; Georgia Soldatos; Merlin C Thomas
Journal:  Clin Biochem Rev       Date:  2005-11

6.  Papaverine increases human serum albumin glycation.

Authors:  Alireza Ahmadzadeh
Journal:  J Biol Phys       Date:  2014-01-12       Impact factor: 1.365

Review 7.  Analysis of carbohydrates and glycoconjugates by matrix-assisted laser desorption/ionization mass spectrometry: An update for 2003-2004.

Authors:  David J Harvey
Journal:  Mass Spectrom Rev       Date:  2009 Mar-Apr       Impact factor: 10.946

8.  Increased concentration of two different advanced glycation end-products detected by enzyme immunoassays with new monoclonal antibodies in sera of patients with rheumatoid arthritis.

Authors:  Richard Vytásek; Liliana Sedová; Vladimír Vilím
Journal:  BMC Musculoskelet Disord       Date:  2010-05-03       Impact factor: 2.362

9.  Nicotine reduces the cytotoxic effect of glycated proteins on microglial cells.

Authors:  Mohammad R Khazaei; Mostafa Bakhti; Mehran Habibi-Rezaei
Journal:  Neurochem Res       Date:  2009-11-28       Impact factor: 3.996

10.  Green tea polyphenol epigallocatechin-3-gallate inhibits advanced glycation end product-induced expression of tumor necrosis factor-alpha and matrix metalloproteinase-13 in human chondrocytes.

Authors:  Zafar Rasheed; Arivarasu N Anbazhagan; Nahid Akhtar; Sangeetha Ramamurthy; Frank R Voss; Tariq M Haqqi
Journal:  Arthritis Res Ther       Date:  2009-05-15       Impact factor: 5.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.